各种全乳与部分乳腺照射技术的第二原发癌长期风险
本研究利用改编的BEIR-VII模型和SEER数据库生存数据计算第二原发癌的终生归因风险(LAR),并在Rando体模中测量各放疗技术对器官的散射剂量。全乳放疗总LAR最高,50岁接受治疗者 excess risk 为4.3%;部分乳腺照射较全乳放疗降低第二原发癌风险2至4倍。
要点
- 全乳放疗总LAR最高,50岁治疗者第二原发癌 excess risk 为4.3%。
- 肺癌占第二原发恶性肿瘤的75%至97%。
- 部分乳腺照射较全乳放疗降低第二原发癌风险2至4倍。
核心结论
- 部分乳腺照射(APBI)较全乳放疗降低第二原发癌风险2至4倍。
- 这些技术适用于预期寿命较长的早期乳腺癌患者。
- 高剂量率近距离放疗和三维适形APBI的平均肺剂量在1至1.5 Gy之间,可作为参考。
研究设计与样本
- 研究采用改编的BEIR-VII形式计算第二原发癌的终生归因风险(LAR),以考虑乳腺癌患者的特定生存情况。
- 生存数据提取自SEER数据库。
- 在Rando体模配合定制乳腺体模中测量散射至各器官的剂量。
- 治疗包括近距离放疗APBI(34 Gy分10次)、三维适形外照射APBI(38.5 Gy分10次)、射波刀立体定向(CK)或VMAT外照射APBI,以及全乳放疗(WBI)42.5 Gy分16次。
主要发现
- 全乳放疗总LAR最高,50岁接受治疗的患者第二原发癌 excess risk 为4.3%。
- 肺癌占第二原发恶性肿瘤的75%至97%。
- 50岁接受治疗的典型早期患者,多导管高剂量率近距离放疗的第二原发肺癌 excess risk 为1.1%。
- 三维适形放疗或射波刀的第二原发肺癌 excess risk 在2.2%至2.5%之间。
- VMAT APBI的第二原发肺癌 excess risk 为3.5%,全乳放疗为3.8%。
关键数值与推荐
- 近距离放疗APBI典型剂量为34 Gy分10次。
- 外照射APBI典型剂量为38.5 Gy分10次。
- 全乳放疗典型剂量为42.5 Gy分16次。
- 高剂量率近距离放疗和三维适形APBI的平均肺剂量在1至1.5 Gy之间,可作为参考。
临床怎么用
- 部分乳腺照射较全乳放疗降低第二原发癌风险2至4倍,这些技术适用于预期寿命较长的早期乳腺癌患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: For early stage breast cancer patients, non-breast cancer mortality including secondary cancers and cardiac events can overshadow the benefit of adjuvant radiotherapy. This study evaluates the excess risk of secondary cancer for various breast radiotherapy techniques including accelerated partial breast irradiation (APBI). METHODS: Secondary cancers Lifetime Attributable Risks (LAR) were calculated using a modified BEIR-VII formalism to account for the specific survival of breast cancer patients. Those survivals were extracted from the SEER database. Doses scattered to various organs were measured into a Rando phantom with custom-made breast phantoms. Treatments delivered typical doses of brachytherapy APBI (34 Gy in 10 fractions), external beam APBI (38.5 Gy in 10 fractions) using 3D-conformal, Cyberknife stereotactic (CK), or VMAT, as well as whole breast irradiation (WBI) delivering 42.5 Gy in 16 fractions. RESULTS: WBI resulted in the highest total LAR, with 4.3% excess risk of secondary cancer for a patient treated at age 50 years. Lung cancers accounted for 75-97% of secondary malignancies. For a typical early stage patient irradiated at 50, the excess risks of secondary lung cancer were 1.1% for multicatheter HDR, between 2.2% and 2.5% for 3D-CRT or CK, 3.5% for VMAT APBI, and 3.8% for WBI. CONCLUSIONS: APBI reduces the risk of secondary cancer 2-4 fold compared to WBI. These techniques are well suited for long-living early stage breast cancer patients. HDR brachytherapy and 3D-conformal APBI achieve mean lung doses between 1 and 1.5 Gy, which could serve as reference.
引用
- Hoekstra N, Fleury E, Merino Lara TR, et al. Long-term risks of secondary cancer for various whole and partial breast irradiation techniques. Radiother Oncol. 2018. PMID: 29914648. doi:10.1016/j.radonc.2018.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。